Gary Raskob to Risk
This is a "connection" page, showing publications Gary Raskob has written about Risk.
Connection Strength
0.327
-
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016 Apr; 115(4):809-16.
Score: 0.126
-
Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med. 2007 Oct; 120(10):901.e1-13.
Score: 0.072
-
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001 Sep 10; 161(16):1952-60.
Score: 0.047
-
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
Score: 0.039
-
Epidemiology and pathogenesis of venous thrombosis. J Am Coll Cardiol. 1986 Dec; 8(6 Suppl B):104B-113B.
Score: 0.017
-
Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 1998 Sep 28; 158(17):1909-12.
Score: 0.010
-
Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992 Apr 09; 326(15):975-82.
Score: 0.006
-
Prophylaxis of venous thromboembolism. An overview. Chest. 1986 May; 89(5 Suppl):374S-383S.
Score: 0.004
-
Risk of haemorrhage associated with long term anticoagulant therapy. Drugs. 1985 Nov; 30(5):444-60.
Score: 0.004
-
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982 Dec 30; 307(27):1676-81.
Score: 0.003